Clinical trial
Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis…
NCT00088504 · Vertex Pharmaceuticals Incorporated, Industry · Completed
Key facts
| NCT number | NCT00088504 |
|---|---|
| Title | Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C |
| Official title | A Phase 2b Study of Merimepodib in Combination With Pegylated Interferon Alfa-2a (Pegasys®) and Ribavirin in Subjects With Chronic Hepatitis C Non-Responsive to Prior Therapy With Pegylated Interferon Alfa and Ribavirin |
| Lead sponsor | Vertex Pharmaceuticals Incorporated, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Hepatitis |
| Intervention type | Drug |
| Interventions | Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®) |
| Enrollment | 315 |
| Start date | Jul 1, 2004 |
| Completion | Oct 1, 2006 |
| First posted | Jul 28, 2004 |
| Last update posted | Dec 21, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: